Cubist/Calixa Deal the Latest in a String of Biotech Buyouts
Cubist Pharmaceuticals has announced plans to acquire tiny San Diego biotech Calixa Therapeutics for up to $402.5 million.
merrimack pharmaceuticals
Adeona’s Experimental RA Drug Does Well in Phase II Trial
Adeona Pharmaceuticals, a developer of medications for CNS and autoimmune diseases, announced data from a Phase II clinical trial of its rheumatoid arthritis drug candidate.
Positive Rheumatoid Arthritis Data for UCB, Trubion, Others
Data presented this weekend at the American College of Rheumatology’s annual meeting indicated that rheumatoid arthritis patients who adhered to a prescription drug regimen had better medical outcomes and lower medical costs.